Beyond multidrug-resistant tuberculosis in Europe: A TBNET study

for the TBNET

doi:10.5588/ijtld.15.0274

Beyond multidrug-resistant tuberculosis in Europe: A TBNET study

for the TBNET

Research output: Contribution to journal › Article › peer-review

28 Citations (Scopus)

Abstract

The emergence of drug-resistant tuberculosis (TB) is a challenge to TB control in Europe.We evaluated secondline drug susceptibility testing in Mycobacterium tuberculosis isolates from patients with multidrugresistant, pre-extensively drug-resistant (pre-XDR-TB) and XDR-TB at 23 TBNET sites in 16 European countries. Over 30% of bacilli from patients with pre-XDR-TB showed resistance to any fluoroquinolone and almost 70% to any second-line injectable drug. Respectively >90% and >80% of the XDR-TB strains tested showed phenotypic resistance to pyrazinamide and ethambutol. Resistance to prothionamide/ethionamide was high in bacilli from pre-XDR-TB patients (43%) and XDR-TB patients (49%).

Original language	English
Pages (from-to)	1524-1527
Number of pages	4
Journal	International Journal of Tuberculosis and Lung Disease
Volume	19
Issue number	12
DOIs	https://doi.org/10.5588/ijtld.15.0274
Publication status	Published - 1 Dec 2015
Externally published	Yes

Bibliographical note

Publisher Copyright:
© 2015 The Union.

Keywords

Drug resistance
Europe
Extensively drug-resistant tuberculosis
MDR-TB
TB
Tuberculosis Network European Trials

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.5588/ijtld.15.0274

Cite this

@article{e15f9de469684db5951ce9d8632a878a,

title = "Beyond multidrug-resistant tuberculosis in Europe: A TBNET study",

abstract = "The emergence of drug-resistant tuberculosis (TB) is a challenge to TB control in Europe.We evaluated secondline drug susceptibility testing in Mycobacterium tuberculosis isolates from patients with multidrugresistant, pre-extensively drug-resistant (pre-XDR-TB) and XDR-TB at 23 TBNET sites in 16 European countries. Over 30\% of bacilli from patients with pre-XDR-TB showed resistance to any fluoroquinolone and almost 70\% to any second-line injectable drug. Respectively >90\% and >80\% of the XDR-TB strains tested showed phenotypic resistance to pyrazinamide and ethambutol. Resistance to prothionamide/ethionamide was high in bacilli from pre-XDR-TB patients (43\%) and XDR-TB patients (49\%).",

keywords = "Drug resistance, Europe, Extensively drug-resistant tuberculosis, MDR-TB, TB, Tuberculosis Network European Trials",

author = "\{for the TBNET\} and G. G{\"u}nther and \{Van Leth\}, F. and N. Altet and M. Dedicoat and R. Duarte and G. Gualano and H. Kunst and I. Muylle and V. Spinu and S. Tiberi and P. Viiklepp and C. Lange",

note = "Publisher Copyright: {\textcopyright} 2015 The Union.",

year = "2015",

month = dec,

day = "1",

doi = "10.5588/ijtld.15.0274",

language = "English",

volume = "19",

pages = "1524--1527",

journal = "International Journal of Tuberculosis and Lung Disease",

issn = "1027-3719",

publisher = "International Union Against Tuberculosis and Lung Disease ",

number = "12",

}

TY - JOUR

T1 - Beyond multidrug-resistant tuberculosis in Europe

T2 - A TBNET study

AU - for the TBNET

AU - Günther, G.

AU - Van Leth, F.

AU - Altet, N.

AU - Dedicoat, M.

AU - Duarte, R.

AU - Gualano, G.

AU - Kunst, H.

AU - Muylle, I.

AU - Spinu, V.

AU - Tiberi, S.

AU - Viiklepp, P.

AU - Lange, C.

PY - 2015/12/1

Y1 - 2015/12/1

N2 - The emergence of drug-resistant tuberculosis (TB) is a challenge to TB control in Europe.We evaluated secondline drug susceptibility testing in Mycobacterium tuberculosis isolates from patients with multidrugresistant, pre-extensively drug-resistant (pre-XDR-TB) and XDR-TB at 23 TBNET sites in 16 European countries. Over 30% of bacilli from patients with pre-XDR-TB showed resistance to any fluoroquinolone and almost 70% to any second-line injectable drug. Respectively >90% and >80% of the XDR-TB strains tested showed phenotypic resistance to pyrazinamide and ethambutol. Resistance to prothionamide/ethionamide was high in bacilli from pre-XDR-TB patients (43%) and XDR-TB patients (49%).

AB - The emergence of drug-resistant tuberculosis (TB) is a challenge to TB control in Europe.We evaluated secondline drug susceptibility testing in Mycobacterium tuberculosis isolates from patients with multidrugresistant, pre-extensively drug-resistant (pre-XDR-TB) and XDR-TB at 23 TBNET sites in 16 European countries. Over 30% of bacilli from patients with pre-XDR-TB showed resistance to any fluoroquinolone and almost 70% to any second-line injectable drug. Respectively >90% and >80% of the XDR-TB strains tested showed phenotypic resistance to pyrazinamide and ethambutol. Resistance to prothionamide/ethionamide was high in bacilli from pre-XDR-TB patients (43%) and XDR-TB patients (49%).

KW - Drug resistance

KW - Europe

KW - Extensively drug-resistant tuberculosis

KW - MDR-TB

KW - TB

KW - Tuberculosis Network European Trials

UR - https://www.scopus.com/pages/publications/84948957364

U2 - 10.5588/ijtld.15.0274

DO - 10.5588/ijtld.15.0274

M3 - Article

C2 - 26614196

AN - SCOPUS:84948957364

SN - 1027-3719

VL - 19

SP - 1524

EP - 1527

JO - International Journal of Tuberculosis and Lung Disease

JF - International Journal of Tuberculosis and Lung Disease

IS - 12

ER -

Beyond multidrug-resistant tuberculosis in Europe: A TBNET study

Abstract

Bibliographical note

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this